Section
This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.
TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.
The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients
This review synthesizes key epidemiologic evidence linking transfusion-related allergic reactions with alpha-gal syndrome (AGS), revealing significant risk in blood type O recipients of B or AB plasma/platelets in AGS-endemic regions.
This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved sur
A French longitudinal study finds no increased long-term complications or compromised quality of life in children under 4 years undergoing TBI-based HSCT for acute lymphoblastic leukemia, challenging prior age restrictions.
A newly identified KMT2A::AFF1-derived fusion circular RNA (AK_7_3) modulates mitochondrial metabolism and apoptosis in t(4;11) B-ALL, revealing potential therapeutic targets for this high-risk leukemia subtype.
This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay fo
This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.
Combining genetic risk stratification with measurable residual disease enables precise treatment allocation in adult Philadelphia chromosome-negative acute lymphoblastic leukemia, improving survival outcomes and guiding the use of allogenei
A quality improvement initiative integrating oral anticoagulants reduced venous thromboembolism incidence in ovarian cancer patients undergoing first-line chemotherapy without increasing bleeding risks.
A randomized pilot trial shows comparable survival and safety outcomes for anti-thymocyte globulin alone versus combined with post-transplant cyclophosphamide, supporting further phase III investigation for graft-versus-host disease prophyl
This review synthesizes real-world data from the DESCAR-T registry on CAR T-cell therapy response kinetics in large B-cell lymphoma, highlighting the prognostic impact of early response patterns and factors influencing conversion from parti
A clustered subset of hotspot PML::RARA mutations drives ATRA resistance in acute promyelocytic leukemia by enhancing basal transcriptional repression rather than disrupting transactivation, suggesting novel mechanisms underlying therapeuti
A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostica
NFE2 drives leukemic transformation through redox regulation, modulating glutathione homeostasis and detoxification pathways, and confers chemotherapy resistance in AML. Targeting NFE2 may enhance therapeutic efficacy and improve patient ou
A hotspot DHX15R222G mutation collaborates with AML1-ETO fusion to enhance mitochondrial function and leukemia stem cell activity, leading to poorer prognosis and chemotherapy resistance in AML, unveiling OXPHOS inhibition as a promising ta
This article reviews the first-in-human study demonstrating durable and safe posttranscriptional silencing of BCL11A in sickle cell disease patients using a shmiR vector, resulting in stable fetal hemoglobin induction and clinical benefit o
This meta-analysis of 17 Phase 3 RCTs reveals that BTK inhibitors, primarily ibrutinib, increase the risk of non-fatal ischemic cardiovascular events in patients with B-cell malignancies, highlighting important safety considerations.
This review synthesizes evidence on health status impairments in long-term TKI-treated CML survivors relative to BMT survivors and non-cancer controls, emphasizing rates of functional impairment, activity limitation, frailty, and quality of
